<DOC>
	<DOCNO>NCT02257424</DOCNO>
	<brief_summary>The primary purpose study determine maximum tolerate dose ( MTD ) preliminary safety hydroxychloroquine ( HCQ ) administer conjunction oral dabrafenib trametinib ( D+T ) patient advance BRAF mutant melanoma .</brief_summary>
	<brief_title>The BAMM Trial : BRAF , Autophagy MEK Inhibition Metastatic Melanoma : A Phase I/2 Trial Dabrafenib , Trametinib Hydroxychloroquine Patients With Advanced BRAF Mutant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Patients must least 18 year age . Patients must histologically confirm diagnosis Stage IV metastatic melanoma positive BRAF V600E V600K CLIA approve assay . Patients must ECOG performance status 0 1 . Patients must adequate baseline organ function determine table 2 . Table 2 . Definitions adequate baseline organ function System Laboratory Values Hematologic ANC 1.2 × 109/L Hemoglobin 9 g/dL Platelet count 100 x 109/L PT/INRa PTT 1.3 x ULN Hepatic Total bilirubin 1.5 x ULNc AST ALT 2.5 x ULN Renal Serum creatinineb 1.5 mg/dL Cardiac Left Ventricular Ejection fraction ( LVEF ) LLN ECHO Abbreviations : ALT = alanine transaminase ; ANC = absolute neutrophil count ; AST = aspartate aminotransferase ; INR = international normalized ratio ; LLN = low limit normal ; PT = prothrombin time ; PTT = partial thromboplastin time ; ULN = upper limit normal . Subjects receive anticoagulation treatment may allow participate INR establish within therapeutic range prior randomization . If serum creatinine &gt; 1.5 mg/dL , calculate creatinine clearance use standard CockcroftGault formula . Creatinine clearance must ≥ 50 mL/min eligible . Except subject know Gilbert 's syndrome . ECHO scan must use throughout study indicate Patients must able provide write informed consent . Negative serum pregnancy test within 7 day prior commencement dose premenopausal woman . Women nonchildbearing potential may include without serum pregnancy test either surgically sterile postmenopausal ≥ 1 year . Women must use effective method contraception 14 day prior randomization , throughout treatment period , least 6 month last dose study treatment direct physician . Effective method contraception define result low failure rate ( i.e. , less 1 % per year ) use consistently correctly ( example implant , injectables , intrauterine device ) . At discretion investigator , acceptable method contraception may include total abstinence case lifestyle patient ensures compliance . ( Periodic abstinence [ e.g. , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) Hormonalbased method ( e.g. , oral contraceptive ) NOT permit contraception due potential drugdrug interaction dabrafenib . Patients brain metastasis treat whole brain radiation stable 2 month eligible ; patient brain metastasis treat gamma knife surgery allow participate 3 week elapse since procedure . Demonstration brain stability image study procedure require gamma knife CNS surgery patient . Subjects exclude leptomeningeal metastasis cause spinal cord compression symptomatic untreated stable ≥3 month ( must document imaging ) require corticosteroid . Subjects stable dose corticosteroid &gt; 1 month corticosteroid least 1 week enrol approval medical monitor Any number type prior anticancer therapy allow except BRAF MEK inhibitor . Patients must discontinue active immunotherapy ( IL2 , interferon , CTLA4 , etc . ) chemotherapy least 4 week prior enter study oral target therapy least 2 week prior enter study . Patients must receive investigational anticancer therapy period study four week prior entry . All prior anticancer treatmentrelated toxicity ( except alopecia laboratory value list Eligibility Criteria # 4 ) must Grade 1 accord Common Terminology Criteria Adverse Events version 4 ( CTCAE version 4.03 , 2009 ) time start treatment . Patients asymptomatic low dose maintenance hormone replacement deliver stable dose prior toxicity eligible . Patient much measurable disease define RECIST 1.1 . Patients must able swallow retain oral medication must clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel . Patients know serious concurrent infection medical illness , include psychiatric disorder , would jeopardize ability patient receive treatment outline protocol reasonable safety . Patients pregnant breastfeeding . Patients receive concurrent therapy tumor ( i.e . chemotherapeutics investigational agent ) . Patients know experience objective partial response immunotherapy time study enrollment History malignancy disease study within 3 year study enrollment exception : Exception : Subjects history completely resect nonmelanoma skin cancer , subject indolent second malignancy eligible History malignancy confirm activate RAS mutation time . Note : Prospective RAS testing require . However , result previous RAS test know , must use assess eligibility . History interstitial lung disease chronic pneumonitis Due risk disease exacerbation patient porphyria psoriasis ineligible unless disease well control care specialist disorder agree monitor patient exacerbation . Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug , excipients dimethyl sulfoxide ( DMSO ) . Patients receive cytochrome P450 enzymeinducing anticonvulsant drug ( EIADs ) ( i.e . phenytoin , carbamazepine , Phenobarbital , primidone oxcarbazepine ) within 4 week start study treatment Current use prohibit medication describe Section 6.3.8 protocol Potential DrugDrug Interaction : apply moisturize cream frequently , topical keratolytics ( e.g . urea 2040 % cream , salicylic acid 6 % , tazarotene 0.1 % cream , fluorouracil 5 % cream ) , clobetasol propionate 0.05 % ointment erythematous area , topical lidocaine 2 % , / systemic pain medication nonsteroidal antiinflammatory drug , codeine , pregabalin pain . Known Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection ( subject laboratory evidence clear HBV and/or HCV permit Patients previously document retinal vein occlusion . History evidence increase cardiovascular risk include follow Left ventricular ejection fraction ( LVEF ) &lt; institutional low limit normal . A QT interval correct heart rate use Bazett 's formula ≥ 480 msec ; Current clinically significant uncontrolled arrhythmia . Exception : Subjects control atrial fibrillation &gt; 30 day prior randomization eligible . History acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month prior randomization . Current ≥ Class II congestive heart failure define New York Heart Association Patients intracardiac defibrillator Abnormal cardiac valve morphology ( ≥grade 2 ) document echocardiogram ( subject grade 1 abnormality [ i.e. , mild regurgitation/stenosis ] enter study ) . Subjects moderate valvular thickening enter study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>